Sanoj Punnen, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    lantheus
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/23/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    telix
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/23/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Foundation One
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/23/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    ExosomeDx
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/23/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Decipher Biosciences
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/23/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Specialty Not Specified)
    Ineligible company: 
    OPKO Diagnostics
    Mitigation strategy: 
    Divest
    Date reviewed: 
    06/23/2023
Return to Treatment for Hormone Sensitive Prostate Cancer (2023)